NASDAQ:IDXG - Interpace Diagnostics Gr Stock Price, Price Target & More

$0.9099 0.00 (0.00 %)

(As of 04/22/2018 04:17 AM ET)

Previous Close$0.9099

Today's Range$0.9010 - $0.93

52-Week Range$0.72 - $3.20

Volume245,151 shs

Average Volume311,500 shs

Market Capitalization$25.34 million

P/E Ratio-1.12

Dividend YieldN/A

Beta1.74

About Interpace Diagnostics Gr (NASDAQ:IDXG)

Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules. The company's customers consist primarily of physicians, hospitals, and clinics. The company was formerly known as PDI, Inc. and changed its name to Interpace Diagnostics Group, Inc. in December 2015. Interpace Diagnostics Group, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

Receive IDXG News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments

Sub-IndustryHealth Care Services

SectorMedical

SymbolNASDAQ:IDXG

CUSIP69329V10

Webwww.interpacediagnostics.com

Phone855-776-6419

Debt

Debt-to-Equity RatioN/A

Current Ratio2.45%

Quick Ratio2.45%

Price-To-Earnings

Trailing P/E Ratio-1.12

Forward P/E Ratio-3.14

P/E GrowthN/A

Sales & Book Value

Annual Sales$15.90 million

Price / Sales1.59

Cash FlowN/A

Price / CashN/A

Book Value$1.48 per share

Price / Book0.61

Profitability

EPS (Most Recent Fiscal Year)($0.81)

Net Income$-12,210,000.00

Net Margins-76.84%

Return on Equity-37.15%

Return on Assets-24.89%

Miscellaneous

Employees75

Outstanding Shares27,870,000

How to Become a New Pot Stock Millionaire

Interpace Diagnostics Gr (NASDAQ:IDXG) Frequently Asked Questions

What is Interpace Diagnostics Gr's stock symbol?

Interpace Diagnostics Gr trades on the NASDAQ under the ticker symbol "IDXG."

How were Interpace Diagnostics Gr's earnings last quarter?

Interpace Diagnostics Gr (NASDAQ:IDXG) issued its quarterly earnings results on Thursday, August, 10th. The business services provider reported ($0.65) earnings per share (EPS) for the quarter. The business services provider had revenue of $3.86 million for the quarter. Interpace Diagnostics Gr had a negative net margin of 76.84% and a negative return on equity of 37.15%. View Interpace Diagnostics Gr's Earnings History.

What price target have analysts set for IDXG?

3 Wall Street analysts have issued 1-year price objectives for Interpace Diagnostics Gr's stock. Their forecasts range from $3.00 to $4.50. On average, they expect Interpace Diagnostics Gr's share price to reach $3.50 in the next twelve months. View Analyst Ratings for Interpace Diagnostics Gr.

Who are some of Interpace Diagnostics Gr's key competitors?

Some companies that are related to Interpace Diagnostics Gr include Neovasc (NVCN), Arch Therapeutics (ARTH), Presbia (LENS), Cellect Biotechnology (APOP), AIT Therapeutics (AITB), Cytori Therapeutics (CYTX), InVivo Therapeutics (NVIV), Valeritas (VLRX), Alliqua BioMedical (ALQA), Neurometrix (NURO), Amedica (AMDA), Avinger (AVGR), STRATA Skin Sciences (SSKN), TearLab (TEAR) and Lombard Medical Technologies (EVARF).

Who are Interpace Diagnostics Gr's key executives?

Interpace Diagnostics Gr's management team includes the folowing people:

Mr. Jack E. Stover, Chief Exec. Officer, Pres and Director (Age 65)
Mr. James E. Early, CFO, Treasurer & Sec. (Age 64)
Mr. Thomas John Freeburg, Chief Accounting Officer (Age 50)
Mr. Frank Arena, Sr. VP of Established Relationship Sales & Commercial Operations
Mr. Gregory Richard, Chief Commercial Officer

Has Interpace Diagnostics Gr been receiving favorable news coverage?

Media stories about IDXG stock have been trending somewhat positive on Sunday, according to Accern Sentiment. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Interpace Diagnostics Gr earned a media sentiment score of 0.18 on Accern's scale. They also assigned press coverage about the business services provider an impact score of 47.19 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

How do I buy shares of Interpace Diagnostics Gr?

Shares of IDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Interpace Diagnostics Gr's stock price today?

One share of IDXG stock can currently be purchased for approximately $0.9099.

How big of a company is Interpace Diagnostics Gr?

Interpace Diagnostics Gr has a market capitalization of $25.34 million and generates $15.90 million in revenue each year. The business services provider earns $-12,210,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Interpace Diagnostics Gr employs 75 workers across the globe.

How can I contact Interpace Diagnostics Gr?

Interpace Diagnostics Gr's mailing address is MORRIS CORPORATE CENTER 1 BUILDING A 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054. The business services provider can be reached via phone at 855-776-6419 or via email at [email protected]

MarketBeat Community Rating for Interpace Diagnostics Gr (IDXG)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		118 (Vote Outperform)
Underperform Votes:		91 (Vote Underperform)
Total Votes:		209

MarketBeat's community ratings are surveys of what our community members think about Interpace Diagnostics Gr and other stocks. Vote "Outperform" if you believe IDXG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXG will underperform the S&P 500 over the long term. You may vote once every thirty days.

Interpace Diagnostics Gr (NASDAQ:IDXG) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

3 Wall Street analysts have issued ratings and price targets for Interpace Diagnostics Gr in the last 12 months. Their average twelve-month price target is $3.50, suggesting that the stock has a possible upside of 284.66%. The high price target for IDXG is $4.50 and the low price target for IDXG is $3.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$3.50	$3.50	$5.00	$5.00
Price Target Upside:	284.66% upside	218.18% upside	290.63% upside	504.23% upside

Interpace Diagnostics Gr (NASDAQ:IDXG) Consensus Price Target History

Price Target History for Interpace Diagnostics Gr (NASDAQ:IDXG)

Interpace Diagnostics Gr (NASDAQ:IDXG) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/6/2018	HC Wainwright	Set Price Target	Buy	$3.00	Medium
3/28/2018	Maxim Group	Set Price Target	Buy	$3.00	High
2/22/2018	Laidlaw	Initiated Coverage	Buy -> Buy	$4.50	High

(Data available from 4/22/2016 forward)

Interpace Diagnostics Gr (NASDAQ:IDXG) Earnings History and Estimates Chart

Earnings by Quarter for Interpace Diagnostics Gr (NASDAQ:IDXG)

Interpace Diagnostics Gr (NASDAQ:IDXG) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.29 EPS
Next Year EPS Consensus Estimate: $-0.19 EPS

Interpace Diagnostics Gr (NASDAQ IDXG) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/13/2017	Q3 2017		($0.15)		$4.20 million	View	N/A
8/10/2017	Q2 2017		($0.65)		$3.86 million	View	N/A
5/15/2017	Q1 2017		$0.42		$3.47 million	View	N/A
3/29/2017	Q4 2016		$3.25		$3.12 million	View	N/A
11/18/2016	Q3 2016		($4.00)		$3.32 million	View	N/A
8/16/2016	Q2 2016		($1.90)		$3.61 million	View	N/A
5/12/2016	Q1 2016		($2.30)		$3.04 million	View	N/A
11/12/2015	Q3	($0.40)	($0.31)	$32.35 million	$36.60 million	View	Listen
8/13/2015	Q215	($0.46)	($0.44)	$32.62 million	$34.10 million	View	Listen
5/12/2015	Q115	($0.48)	($0.25)	$33.20 million	$38.30 million	View	Listen
3/3/2015	Q414	($0.50)	($0.27)	$140.87 million	$28.90 million	View	Listen
11/3/2014	Q3	($0.19)	($0.29)	$33.40 million	$29.20 million	View	Listen
8/13/2014	Q2	($0.12)	($0.17)	$35.60 million	$31.60 million	View	Listen
5/7/2014	Q1	($0.11)	($0.11)	$39.48 million	$32.80 million	View	Listen
2/27/2014	Q4	($0.11)	($0.25)	$38.09 million	$36.41 million	View	Listen
11/12/2013	Q3	($0.23)	($0.14)	$37.98 million	$34.26 million	View	Listen
8/5/2013	Q2 2013	($0.11)	($0.06)	$35.26 million	$37.20 million	View	Listen
5/13/2013	Q1 2013	($1.10)	$1.40	$38.02 million	$42.92 million	View	N/A
3/6/2013	Q4 2012	($0.07)	($1.64)	$36.90 million	$35.60 million	View	Listen
11/5/2012	Q3 2012	($0.40)	($0.60)			View	N/A
8/13/2012	Q2 2012	($0.70)	($0.27)			View	N/A
5/14/2012	Q1 2012	$0.20	($0.21)			View	N/A
3/7/2012	Q4 2011	($0.40)	($0.01)			View	N/A
11/9/2011	Q3 2011	($0.60)	($0.13)			View	N/A
8/8/2011	Q2 2011	($1.10)	($0.61)			View	N/A
5/3/2011	Q1 2011	($0.90)	($0.37)			View	N/A
3/21/2011	Q4 2010	$0.20	($1.17)			View	N/A
11/3/2010	Q3 2010	($1.10)	$0.28			View	N/A
8/4/2010	Q2 2010	($2.00)	($0.62)			View	N/A
5/6/2010	Q1 2010	($0.90)	($1.19)			View	N/A
3/4/2010	Q4 2009	($1.80)	($0.99)			View	N/A
11/5/2009	Q3 2009	($3.50)	($3.21)			View	N/A
8/5/2009	Q2 2009	($4.00)	($3.40)			View	N/A
5/6/2009	Q1 2009		($4.00)			View	N/A
3/11/2009	Q4 2008	($7.00)	($12.03)			View	N/A
11/6/2008	Q3 2008		($6.42)			View	N/A
8/6/2008	Q2 2008		($5.30)			View	N/A
5/8/2008	Q1 2008	($1.70)	($0.76)			View	N/A
3/12/2008	Q4 2007		($1.09)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Interpace Diagnostics Gr (NASDAQ:IDXG) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Interpace Diagnostics Gr (NASDAQ IDXG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.70%
Institutional Ownership Percentage: 13.11%

Insider Trading History for Interpace Diagnostics Gr (NASDAQ:IDXG)

Institutional Ownership by Quarter for Interpace Diagnostics Gr (NASDAQ:IDXG)

Interpace Diagnostics Gr (NASDAQ IDXG) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/25/2014	Graham G Miao	CFO	Buy	22,000	$1.65	$36,300.00
11/10/2014	Nancy Lurker	CEO	Buy	49,000	$1.75	$85,750.00
11/7/2014	Gerald R Melillo Jr	Insider	Buy	5,000	$1.58	$7,900.00
11/7/2014	Jeffrey Edward Smith	VP	Buy	200,000	$1.75	$350,000.00
11/6/2014	Nancy Lurker	CEO	Buy	57,000	$1.74	$99,180.00
11/5/2014	Gerald P Belle	Director	Buy	57,300	$1.71	$97,983.00
11/18/2013	Gerald Belle	Director	Buy	20,400	$5.21	$106,284.00	84,357

(Data available from 1/1/2013 forward)

Interpace Diagnostics Gr (NASDAQ IDXG) News Headlines

Source:

Date	Headline
	Interpace Diagnostics Gr (IDXG) Given Average Recommendation of "Strong Buy" by Brokerages www.americanbankingnews.com - April 22 at 3:12 AM
	Interpace Diagnostics Gr (IDXG) PT Set at $3.00 by HC Wainwright www.americanbankingnews.com - April 6 at 11:06 AM
	Interpace Diagnostics Gr (IDXG) Downgraded to "Strong Sell" at ValuEngine www.americanbankingnews.com - April 3 at 1:52 PM
	Active-Investors: Free Research Report as Verisk's Quarterly Revenue Jumped 12.7%; Adjusted EPS Soared 67.5% www.finanznachrichten.de - April 2 at 8:30 AM
	Free Research Report as Verisk’s Quarterly Revenue Jumped 12.7%; Adjusted EPS Soared 67.5% finance.yahoo.com - April 2 at 8:30 AM
	Interpace Diagnostics Gr (IDXG) Receives Average Rating of "Strong Buy" from Brokerages www.americanbankingnews.com - March 31 at 3:18 PM
	Acupath to promote Interpace thyroid tests seekingalpha.com - March 28 at 5:23 PM
	Interpace Diagnostics Gr (IDXG) Given a $3.00 Price Target by Maxim Group Analysts www.americanbankingnews.com - March 28 at 2:04 PM
	Interpace Diagnostics Gr (IDXG) Upgraded by ValuEngine to "Sell" www.americanbankingnews.com - March 25 at 5:22 PM
	Interpace Diagnostics Announces Expansion of LabCorp National Agreement finance.yahoo.com - March 20 at 8:21 AM
	Interpace Diagnostics Group (IDXG) PT Set at $3.00 by Maxim Group www.americanbankingnews.com - March 16 at 8:20 PM
	Edited Transcript of IDXG earnings conference call or presentation 15-Mar-18 8:30pm GMT finance.yahoo.com - March 16 at 6:33 PM
	Interpace Diagnostics Group's (IDXG) "Buy" Rating Reiterated at HC Wainwright www.americanbankingnews.com - March 16 at 1:48 PM
	Interpace Diagnostics Announces Timing of Earnings Release and ... - GlobeNewswire (press release) globenewswire.com - March 15 at 8:11 AM
	Worldpay (WP) and Interpace Diagnostics Group (IDXG) Critical Contrast www.americanbankingnews.com - March 12 at 9:13 PM
	Interpace Diagnostics Announces Additional Coverage of Thyroid Tests - GlobeNewswire (press release) globenewswire.com - March 10 at 8:17 AM
	New Research Coverage Highlights Great Western, Acadia Realty Trust, Interpace Diagnostics Group, Abercrombie & Fitch, United Rentals, and ZIOPHARM Oncology — Consolidated Revenues, Company Growth, and Expectations for 2018 finance.yahoo.com - March 9 at 8:14 AM
	Interpace Diagnostics Group (IDXG) Research Coverage Started at HC Wainwright www.americanbankingnews.com - March 8 at 11:40 PM
	HC Wainwright Takes Bullish Stance On Interpace Diagnostics ... - Benzinga www.benzinga.com - March 8 at 6:52 PM
	Interpace Diagnostics Announces Additional Coverage of Thyroid Tests finance.yahoo.com - March 8 at 6:52 PM
	Interpace Diagnostics Announces Additional Coverage of Thyroid Tests - Nasdaq www.nasdaq.com - March 8 at 8:16 AM
	Interpace Diagnostics (IDXG) Announces Additional Coverage of Thyroid Tests - StreetInsider.com www.streetinsider.com - March 8 at 8:16 AM
	Comparing Interpace Diagnostics Group (IDXG) and Nelnet (NNI) www.americanbankingnews.com - March 5 at 1:52 PM
	Interpace Diagnostics' (IDXG) Says Horizon Blue Cross Blue Shield of New Jersey to Cover its Molecular Thyroid Tests www.streetinsider.com - February 27 at 5:58 PM
	Interpace Diagnostics' (IDXG) Says Horizon Blue Cross Blue Shield of New Jersey to Cover its Molecular Thyroid Tests - StreetInsider.com www.streetinsider.com - February 27 at 8:14 AM
	Interpace Diagnostics' CEO Interviewed on The RedChip Money ... - GlobeNewswire (press release) globenewswire.com - February 23 at 8:16 AM
	Interpace Diagnostics Group (IDXG) Research Coverage Started at Laidlaw www.americanbankingnews.com - February 22 at 3:02 PM
	Interpace Diagnostics Group Inc (IDXG) PT Lowered to $3 at Maxim Group - StreetInsider.com www.streetinsider.com - February 16 at 8:14 AM
	Interpace Diagnostics Group (IDXG) Given a $3.00 Price Target by Maxim Group Analysts www.americanbankingnews.com - February 14 at 10:40 PM
	Interpace Diagnostics to Present Data on Thyroid, Pancreatic, and Lung Assays finance.yahoo.com - February 12 at 9:07 AM
	Analyzing MAXIMUS (MMS) & Interpace Diagnostics Group (IDXG) www.americanbankingnews.com - January 26 at 9:06 AM
	Interpace Diagnostics to Present at NobleCon14 on January 29 finance.yahoo.com - January 25 at 9:05 AM
	Interpace Diagnostics Recognized as One of the Top 20 Bioinformatics Solutions Providers - GlobeNewswire (press release) globenewswire.com - January 8 at 4:00 PM
	What Does Interpace Diagnostics Group Inc’s (NASDAQ:IDXG) Share Price Indicate? finance.yahoo.com - January 6 at 6:30 AM
	Comparing Interpace Diagnostics Group (IDXG) & Lifelock (LOCK) www.americanbankingnews.com - December 28 at 7:34 PM
	Interpace Diagnostics Announces Agreement with ARUP Laboratories - GlobeNewswire (press release) globenewswire.com - December 19 at 3:53 PM
	Interpace Diagnostics Group (IDXG) and Willdan Group (WLDN) Financial Survey www.americanbankingnews.com - December 19 at 1:26 AM
	Interpace Diagnostics Group, Inc. :IDXG-US: Earnings Analysis: Q3, 2017 By the Numbers : December 18, 2017 finance.yahoo.com - December 18 at 11:37 AM
	Contrasting Interpace Diagnostics Group (IDXG) & Ritchie Bros. Auctioneers (RBA) www.americanbankingnews.com - November 24 at 3:28 AM
	Head-To-Head Analysis: Unifirst Corporation (UNF) versus Interpace Diagnostics Group (IDXG) www.americanbankingnews.com - November 18 at 3:37 AM
	BRIEF-Interpace Diagnostics says ‍New York State Department Of Health approved its TERT service offering www.reuters.com - November 17 at 6:40 PM
	Interpace Diagnostics Announces New York State Approval of New Product finance.yahoo.com - November 17 at 5:36 AM
	Interpace Diagnostics Group, Inc. (IDXG) Rating Reiterated by Maxim Group www.americanbankingnews.com - November 14 at 1:14 PM
	BRIEF-Interpace Diagnostics says Q3 sales up 27 pct www.reuters.com - November 14 at 12:51 AM
	Edited Transcript of IDXG earnings conference call or presentation 13-Nov-17 1:30pm GMT finance.yahoo.com - November 14 at 12:51 AM
	Interpace Diagnostics Group's (IDXG) CEO Jack Stover on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha seekingalpha.com - November 13 at 7:49 PM
	Interpace Diagnostics Group Reports Third Quarter 2017 Financial Results, Business Progress and Recent Accomplishments finance.yahoo.com - November 13 at 7:49 PM
	Interpace Diagnostics to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results and Business Progress on Monday November 13, 2017 finance.yahoo.com - November 11 at 11:14 AM
	Ituran Location and Control (ITRN) & Interpace Diagnostics Group (IDXG) Financial Contrast www.americanbankingnews.com - November 7 at 9:36 PM
	Recent VRSK News www.bloomberg.com - November 2 at 1:52 AM

Interpace Diagnostics Gr (NASDAQ:IDXG) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Interpace Diagnostics Gr (NASDAQ:IDXG) Income Statement, Balance Sheet and Cash Flow Statement

Interpace Diagnostics Gr (NASDAQ IDXG) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff